• Cat-intel
  • MedIntelliX
  • Consulting
  • Resources
  • About Us
  • News
  • Careers
  • Contact Us
  • Login
    • Request Free Sample ×
    ReportInfographic

    Kindly complete the form below to receive a free sample of this Report

    Leading companies partner with us for data-driven Insights

    clients tt-cursor

    GCC Companion Diagnostics Oncology Market

    ID: MRFR/MED/48455-HCR
    200 Pages
    Rahul Gotadki
    September 2025

    GCC Companion Diagnostics Oncology Market Research Report By Technology (Next Generation Sequencing, Polymerase Chain Reaction, In Situ Hybridization, Immunohistochemistry), By Applications (Therapeutic Monitoring, Patient Stratification, Predictive Testing, Disease Diagnosis), By End-user (Hospitals, Diagnostic Laboratories, Research Institutions, Pharmaceutical Companies), and By Test Type (Genetic Tests, Protein Biomarker Tests, MicroRNA Tests, Pathological Analysis)- Forecast to 2035

    Share:
    Download PDF ×

    We do not share your information with anyone. However, we may send you emails based on your report interest from time to time. You may contact us at any time to opt-out.

    GCC Companion Diagnostics Oncology Market Research Report- Forecast to 2035 Infographic
    Purchase Options
    $ 4,950.0
    $ 5,950.0
    $ 7,250.0
    Compare License
    Table of Contents

    GCC Companion Diagnostics Oncology Market Summary

    The GCC Companion Diagnostics Oncology market is projected to grow significantly from 142.8 USD Million in 2024 to 357 USD Million by 2035.

    Key Market Trends & Highlights

    GCC Companion Diagnostics Oncology Key Trends and Highlights

    • The market is expected to achieve a compound annual growth rate (CAGR) of 8.69 percent from 2025 to 2035.
    • By 2035, the market valuation is anticipated to reach 357 USD Million, indicating robust growth potential.
    • In 2024, the market is valued at 142.8 USD Million, reflecting the current demand for companion diagnostics in oncology.
    • Growing adoption of personalized medicine due to increasing cancer prevalence is a major market driver.

    Market Size & Forecast

    2024 Market Size 142.8 (USD Million)
    2035 Market Size 357 (USD Million)
    CAGR (2025-2035) 8.69%

    Major Players

    Illumina, Novartis, AstraZeneca, QIAGEN, Bristol-Myers Squibb, Abbott Laboratories, F. Hoffmann La Roche, Genoptix, Thermo Fisher Scientific, Agilent Technologies, Pfizer, Roche, Johnson and Johnson, GSK, Merck KGaA

    GCC Companion Diagnostics Oncology Market Trends

    Increased awareness of personalized treatment and biotechnology breakthroughs are driving notable trends in the GCC Companion Diagnostics Oncology Market. The GCC's governments are boosting cancer care initiatives, supporting precision medicine, and investing in healthcare infrastructure. Companion diagnostics are positioned as essential tools in the oncology landscape by initiatives like the UAE's National Cancer Strategy.

    This strategy is in line with the increased emphasis on customised treatment options. Opportunities for cooperation between pharmaceutical companies and diagnostics developers are being created by the rising emphasis on early diagnosis and focused therapy. Additionally, the need for novel companion diagnostic solutions is being fuelled by the rise in demand for genetic testing and biomarker analysis.

    This pattern is consistent with rising cancer rates and an expanding patient population in GCC nations, underscoring the need for cutting-edge diagnostic techniques that support efficient treatment strategies. Furthermore, the GCC countries' healthcare systems are increasingly becoming more aware of the advantages of companion diagnostics, which is making patients and healthcare professionals more knowledgeable and open to implementing these technologies.

    Companion diagnostics are also receiving increased support from regional regulatory agencies, who are expediting approval procedures to promote market expansion and entrance. As stakeholders strive to improve treatment results and patient care through cooperation, innovation, and strategic investments in oncology companion diagnostics, the GCC market offers a unique convergence of opportunity.

    GCC Companion Diagnostics Oncology Market Drivers

    Market Segment Insights

    Companion Diagnostics Oncology Market Technology Insights

    The Technology segment within the GCC Companion Diagnostics Oncology Market represents a crucial component in the advancement of personalized medicine, which has gained significant traction in recent years owing to its potential to enhance cancer treatment efficacy. Driven by the increasing prevalence of oncology-related disorders and a strong focus on tailored therapies, this segment showcases an array of advanced technological methodologies.

    Among these, Next Generation Sequencing stands out for its ability to rapidly sequence DNA, offering insights into genetic mutations and facilitating not only the detection of tumors but also the selection of targeted treatments, thereby significantly improving patient outcomes. Polymerase Chain Reaction, another key methodology, provides a means to amplify and analyze DNA sequences and is integral to early disease detection, enabling more timely and effective interventions.

    In Situ Hybridization plays a vital role by allowing researchers and clinicians to visualize and localize specific RNA or DNA within tissue samples, thereby aiding in the understanding of tumor biology and the identification of actionable targets for therapy. Immunohistochemistry is equally essential, as it employs antibodies to detect specific proteins in cancerous tissues, thus providing critical information regarding tumor classification and guiding treatment decisions.

    The GCC region has seen an increasing investment in advanced technologies, which is supported by government initiatives focusing on enhancing healthcare infrastructure and research capabilities, creating a fertile ground for innovation and growth in the oncology domain. As the demand for personalized medicine rises, these technological advancements are expected to significantly influence the GCC Companion Diagnostics Oncology Market, providing both challenges and opportunities that healthcare providers must navigate to optimize patient care and outcomes.

    Source: Primary Research, Secondary Research, Market Research Future Database and Analyst Review

    Companion Diagnostics Oncology Market Applications Insights

    The Applications segment of the GCC Companion Diagnostics Oncology Market plays a pivotal role in enhancing patient care through precision medicine. Within this segment, Therapeutic Monitoring is essential for evaluating patient response to treatment, allowing healthcare providers to adjust therapies for optimal effectiveness. Patient Stratification is important as it identifies suitable individuals for specific treatments, improving outcomes and minimizing adverse effects.

    Predictive Testing serves a critical function by assessing the likelihood of disease occurrence or recurrence and guiding preventive strategies. Disease Diagnosis is foundational in confirming cancer types and stages, thus influencing treatment plans. The increasing prevalence of cancer in the GCC region, coupled with government initiatives to promote personalized medicine, drives the demand for these applications.

    Moreover, as healthcare systems in GCC countries strive for improved patient outcomes and cost-effectiveness, the importance of these applications becomes even more significant, making them vital components in the overall landscape of the GCC Companion Diagnostics Oncology Market. This growth is further fueled by advancements in technology and an increasing focus on tailored therapies designed to meet the unique genetic profiles of patients in the region.

    Companion Diagnostics Oncology Market End-user Insights

    The End-user segment of the GCC Companion Diagnostics Oncology Market is pivotal for the overall landscape of oncology care within the region. Hospitals play a critical role as they integrate diagnostics into patient treatment plans, facilitating personalized medicine. Diagnostic Laboratories provide essential testing services that enable the identification of biomarkers for various cancers, significantly enhancing the precision of treatment protocols.

    Research Institutions also contribute by conducting innovative studies focused on the development of new diagnostic tools, thereby fostering advancements in oncology research within the GCC. Furthermore, Pharmaceutical Companies are integral as they collaborate closely with diagnostics to ensure therapies are effectively matched to patient profiles, improving clinical outcomes.

    These segments collectively witness an increased demand for tailored therapies, driven by rising cancer incidences and a growing emphasis on personalized medicine strategies. The evolving healthcare policies in GCC countries support investments in oncology diagnostics, propelling market growth and enhancing the overall health infrastructure in the region. The collaboration between these entities underscores the importance of companion diagnostics and their role in transforming oncology treatment pathways.

    Companion Diagnostics Oncology Market Test Type Insights

    The GCC Companion Diagnostics Oncology Market emphasizes a range of Test Types integral to advancing personalized medicine in oncology. Genetic Tests play a pivotal role, aiding in the identification of mutations that guide targeted therapies, thereby enhancing treatment outcomes. Similarly, Protein Biomarker Tests are essential for measuring specific proteins associated with cancer, enabling clinicians to make informed decisions about patient management.

    MicroRNA Tests represent a cutting-edge approach, as they have the potential to uncover novel biomarkers for early cancer detection and prognosis, indicating their growing importance in the field. Pathological Analysis remains a cornerstone in cancer diagnostics, providing comprehensive insights into tissue samples to determine the type and stage of cancer.

    The segmentation within the GCC Companion Diagnostics Oncology Market is driven by the increasing prevalence of cancer cases and the rising demand for precision medicine, which fosters innovations and research in these testing methodologies. As the healthcare sector in the GCC continues to evolve, these Test Types are set to play a crucial role in improving patient outcomes and healthcare efficiency in oncology.

    Get more detailed insights about GCC Companion Diagnostics Oncology Market Research Report- Forecast to 2035

    Request Free Sample

    Regional Insights

    Key Players and Competitive Insights

    The GCC Companion Diagnostics Oncology Market is a rapidly evolving sector characterized by a growing emphasis on personalized medicine and targeted therapies. This market has gained significant traction due to the increasing prevalence of cancer across the Gulf Cooperation Council member states. As healthcare systems in the region shift towards more precise treatment options, the demand for companion diagnostics—tools that aid in determining patient eligibility for specific therapies—has intensified.

    Competitive insights reveal a landscape where innovation, regulatory compliance, and partnerships play crucial roles as stakeholders, including biotechnology firms, pharmaceutical companies, and healthcare providers, aim to establish robust footholds in an increasingly sophisticated market. Companies are leveraging technological advancements and market data to enhance their product offerings, develop effective market strategies, and ultimately improve patient outcomes.

    Illumina

    Illumina has established a significant presence in the GCC Companion Diagnostics Oncology Market, leveraging its expertise in next-generation sequencing technologies. The company's strengths lie in its advanced genomic solutions that facilitate accurate patient profiling, which is critical for the development and administration of targeted cancer therapies. Illumina's innovative platforms enable clinicians to make informed decisions regarding treatment plans, directly improving outcomes for cancer patients in the region.

    With a commitment to enhancing patient care through technology, Illumina's collaborations with local healthcare providers and research institutions further solidify its market position. By providing comprehensive support and resources, Illumina actively contributes to the evolution of precision medicine in the GCC, addressing the unique oncology needs of the population while driving research advancements.

    Novartis

    Novartis plays a pivotal role in the GCC Companion Diagnostics Oncology Market, focusing on the intersection of oncology pharmaceuticals and diagnostic tools. The company has developed several key products aimed at improving patient management in various cancer types, leveraging their diagnostic platforms to identify eligible patients for their targeted therapies.

    Novartis's strengths in this region are amplified by its significant investments in partnerships with healthcare institutions and research organizations, which enhance its market presence and product development capabilities. In addition, strategic mergers and acquisitions have expanded Novartis's portfolio, allowing the company to integrate innovative diagnostics into its therapeutic offerings.

    This holistic approach not only enables Novartis to respond effectively to the evolving needs of oncology care in the GCC but also reinforces its commitment to delivering tailored solutions that enhance patient outcomes across the region.

    Key Companies in the GCC Companion Diagnostics Oncology Market market include

    Industry Developments

    In recent developments within the GCC Companion Diagnostics Oncology Market, companies such as Illumina, Novartis, and AstraZeneca have intensified their focus on expanding their oncology programs. For instance, in March 2023, Illumina launched its latest sequencing technology tailored for oncology applications, aiming to enhance personalized medicine in GCC countries.

    Additionally, in July 2023, Novartis announced a strategic partnership with a local biotechnology firm to streamline access to companion diagnostics in the Middle East. AstraZeneca has also made significant strides, expanding its oncology portfolio through collaborations with regional health authorities.

    Meanwhile, mergers and acquisitions are shaping the competitive landscape. Notably, in January 2023, Merck KGaA acquired a local diagnostics company to bolster its presence in the region, aligning with the growing market demand for comprehensive cancer care solutions.

    The GCC region has seen substantial growth in the companion diagnostics market, influenced by rising cancer incidences and increasing healthcare initiatives by governments such as Saudi Arabia and the UAE to enhance healthcare infrastructure. Consequently, companies like QIAGEN and Roche are also investing in local collaborations, which is further driving advancements in this sector. Market valuations have significantly increased, drawing more investments and driving innovation across the field.

    Market Segmentation

    Companion Diagnostics Oncology Market End-user Outlook

    • Hospitals
    • Diagnostic Laboratories
    • Research Institutions
    • Pharmaceutical Companies

    Companion Diagnostics Oncology Market Test Type Outlook

    • Genetic Tests
    • Protein Biomarker Tests
    • MicroRNA Tests
    • Pathological Analysis

    Companion Diagnostics Oncology Market Technology Outlook

    • Next Generation Sequencing
    • Polymerase Chain Reaction
    • In Situ Hybridization
    • Immunohistochemistry

    Companion Diagnostics Oncology Market Applications Outlook

    • Therapeutic Monitoring
    • Patient Stratification
    • Predictive Testing
    • Disease Diagnosis

    Report Scope

    Report Attribute/Metric Source: Details
    MARKET SIZE 2023 133.0(USD Million)
    MARKET SIZE 2024 142.75(USD Million)
    MARKET SIZE 2035 357.0(USD Million)
    COMPOUND ANNUAL GROWTH RATE (CAGR) 8.69% (2025 - 2035)
    REPORT COVERAGE Revenue Forecast, Competitive Landscape, Growth Factors, and Trends
    BASE YEAR 2024
    MARKET FORECAST PERIOD 2025 - 2035
    HISTORICAL DATA 2019 - 2024
    MARKET FORECAST UNITS USD Million
    KEY COMPANIES PROFILED Illumina, Novartis, AstraZeneca, QIAGEN, BristolMyers Squibb, Abbott Laboratories, F. HoffmannLa Roche, Genoptix, Thermo Fisher Scientific, Agilent Technologies, Pfizer, Roche, Johnson and Johnson, GSK, Merck KGaA
    SEGMENTS COVERED Technology, Applications, End User, Test Type
    KEY MARKET OPPORTUNITIES Rising cancer prevalence, Advanced genetic testing demand, Increased personalized medicine adoption, Government healthcare initiatives, Collaborations with biotech firms
    KEY MARKET DYNAMICS Increasing prevalence of cancer, Rising demand for personalized medicine, Advances in molecular diagnostics, Growing government initiatives, Lack of regulatory framework
    COUNTRIES COVERED GCC

    Market Highlights

    Author
    Rahul Gotadki
    Assistant Manager

    He holds an experience of about 7+ years in Market Research and Business Consulting, working under the spectrum of Life Sciences and Healthcare domains. Rahul conceptualizes and implements a scalable business strategy and provides strategic leadership to the clients. His expertise lies in market estimation, competitive intelligence, pipeline analysis, customer assessment, etc. In addition to the above, his other responsibility includes strategic tracking of high growth markets & advising clients on the potential areas of focus they could direct their business initiatives

    Get In Touch
    Leave a Comment

    FAQs

    What is the expected market size of the GCC Companion Diagnostics Oncology Market in 2024?

    The expected market size of the GCC Companion Diagnostics Oncology Market in 2024 is valued at 142.75 million USD.

    What is the projected market value for the GCC Companion Diagnostics Oncology Market by 2035?

    The projected market value for the GCC Companion Diagnostics Oncology Market by 2035 is estimated to reach 357.0 million USD.

    What is the expected CAGR for the GCC Companion Diagnostics Oncology Market from 2025 to 2035?

    The expected CAGR for the GCC Companion Diagnostics Oncology Market from 2025 to 2035 is 8.69 percent.

    Which technology is expected to dominate the GCC Companion Diagnostics Oncology Market in 2024?

    In 2024, Immunohistochemistry is expected to dominate the GCC Companion Diagnostics Oncology Market, valued at 52.75 million USD.

    What market size do the Next Generation Sequencing and Polymerase Chain Reaction technologies hold in 2024?

    In 2024, Next Generation Sequencing is valued at 35.0 million USD and Polymerase Chain Reaction at 30.0 million USD.

    How do the market values of In Situ Hybridization and Immunohistochemistry compare in 2035?

    By 2035, In Situ Hybridization is expected to be valued at 62.5 million USD while Immunohistochemistry will be at 130.75 million USD.

    Who are the key players in the GCC Companion Diagnostics Oncology Market?

    Key players in the GCC Companion Diagnostics Oncology Market include Illumina, Novartis, and AstraZeneca among others.

    What opportunities and growth drivers are present in the GCC Companion Diagnostics Oncology Market?

    Opportunities in the market include the increasing prevalence of oncology diseases and advancements in diagnostic technologies.

    What is the impact of the current global scenario on the GCC Companion Diagnostics Oncology Market?

    The current global scenario impacts the market by influencing investment patterns and innovation in healthcare solutions.

    What is the growth rate of the GCC Companion Diagnostics Oncology Market expected to be for specific technologies by 2035?

    By 2035, the market for Next Generation Sequencing is expected to grow to 88.75 million USD and for Polymerase Chain Reaction to 75.0 million USD.

    1. EXECUTIVE
    2. SUMMARY
    3. Market Overview
    4. Key Findings
    5. Market Segmentation
    6. Competitive Landscape
    7. Challenges and Opportunities
    8. Future Outlook
    9. MARKET INTRODUCTION
    10. Definition
    11. Scope of the study
    12. Research Objective
    13. Assumption
    14. Limitations
    15. RESEARCH
    16. METHODOLOGY
    17. Overview
    18. Data
    19. Mining
    20. Secondary Research
    21. Primary
    22. Research
    23. Primary Interviews and Information Gathering
    24. Process
    25. Breakdown of Primary Respondents
    26. Forecasting
    27. Model
    28. Market Size Estimation
    29. Bottom-Up
    30. Approach
    31. Top-Down Approach
    32. Data
    33. Triangulation
    34. Validation
    35. MARKET
    36. DYNAMICS
    37. Overview
    38. Drivers
    39. Restraints
    40. Opportunities
    41. MARKET FACTOR ANALYSIS
    42. Value chain Analysis
    43. Porter's
    44. Five Forces Analysis
    45. Bargaining Power of Suppliers
    46. Bargaining
    47. Power of Buyers
    48. Threat of New Entrants
    49. Threat
    50. of Substitutes
    51. Intensity of Rivalry
    52. COVID-19
    53. Impact Analysis
    54. Market Impact Analysis
    55. Regional
    56. Impact
    57. Opportunity and Threat Analysis
    58. GCC
    59. Companion Diagnostics Oncology Market, BY Technology (USD Million)
    60. Next
    61. Generation Sequencing
    62. Polymerase Chain Reaction
    63. In
    64. Situ Hybridization
    65. Immunohistochemistry
    66. GCC
    67. Companion Diagnostics Oncology Market, BY Applications (USD Million)
    68. Therapeutic
    69. Monitoring
    70. Patient Stratification
    71. Predictive
    72. Testing
    73. Disease Diagnosis
    74. GCC
    75. Companion Diagnostics Oncology Market, BY End User (USD Million)
    76. Hospitals
    77. Diagnostic
    78. Laboratories
    79. Research Institutions
    80. Pharmaceutical
    81. Companies
    82. GCC Companion Diagnostics
    83. Oncology Market, BY Test Type (USD Million)
    84. Genetic
    85. Tests
    86. Protein Biomarker Tests
    87. MicroRNA
    88. Tests
    89. Pathological Analysis
    90. Competitive Landscape
    91. Overview
    92. Competitive
    93. Analysis
    94. Market share Analysis
    95. Major
    96. Growth Strategy in the Companion Diagnostics Oncology Market
    97. Competitive
    98. Benchmarking
    99. Leading Players in Terms of Number of Developments
    100. in the Companion Diagnostics Oncology Market
    101. Key developments
    102. and growth strategies
    103. New Product Launch/Service Deployment
    104. Merger
    105. & Acquisitions
    106. Joint Ventures
    107. Major
    108. Players Financial Matrix
    109. Sales and Operating Income
    110. Major
    111. Players R&D Expenditure. 2023
    112. Company
    113. Profiles
    114. Illumina
    115. Financial
    116. Overview
    117. Products Offered
    118. Key
    119. Developments
    120. SWOT Analysis
    121. Key
    122. Strategies
    123. Novartis
    124. Financial
    125. Overview
    126. Products Offered
    127. Key
    128. Developments
    129. SWOT Analysis
    130. Key
    131. Strategies
    132. AstraZeneca
    133. Financial
    134. Overview
    135. Products Offered
    136. Key
    137. Developments
    138. SWOT Analysis
    139. Key
    140. Strategies
    141. QIAGEN
    142. Financial
    143. Overview
    144. Products Offered
    145. Key
    146. Developments
    147. SWOT Analysis
    148. Key
    149. Strategies
    150. BristolMyers Squibb
    151. Financial
    152. Overview
    153. Products Offered
    154. Key
    155. Developments
    156. SWOT Analysis
    157. Key
    158. Strategies
    159. Abbott Laboratories
    160. Financial
    161. Overview
    162. Products Offered
    163. Key
    164. Developments
    165. SWOT Analysis
    166. Key
    167. Strategies
    168. F. HoffmannLa Roche
    169. Financial
    170. Overview
    171. Products Offered
    172. Key
    173. Developments
    174. SWOT Analysis
    175. Key
    176. Strategies
    177. Genoptix
    178. Financial
    179. Overview
    180. Products Offered
    181. Key
    182. Developments
    183. SWOT Analysis
    184. Key
    185. Strategies
    186. Thermo Fisher Scientific
    187. Financial
    188. Overview
    189. Products Offered
    190. Key
    191. Developments
    192. SWOT Analysis
    193. Key
    194. Strategies
    195. Agilent Technologies
    196. Financial
    197. Overview
    198. Products Offered
    199. Key
    200. Developments
    201. SWOT Analysis
    202. Key
    203. Strategies
    204. Pfizer
    205. Financial
    206. Overview
    207. Products Offered
    208. Key
    209. Developments
    210. SWOT Analysis
    211. Key
    212. Strategies
    213. Roche
    214. Financial
    215. Overview
    216. Products Offered
    217. Key
    218. Developments
    219. SWOT Analysis
    220. Key
    221. Strategies
    222. Johnson and Johnson
    223. Financial
    224. Overview
    225. Products Offered
    226. Key
    227. Developments
    228. SWOT Analysis
    229. Key
    230. Strategies
    231. GSK
    232. Financial
    233. Overview
    234. Products Offered
    235. Key
    236. Developments
    237. SWOT Analysis
    238. Key
    239. Strategies
    240. Merck KGaA
    241. Financial
    242. Overview
    243. Products Offered
    244. Key
    245. Developments
    246. SWOT Analysis
    247. Key
    248. Strategies
    249. References
    250. Related
    251. Reports
    252. LIST
    253. OF ASSUMPTIONS
    254. GCC Companion Diagnostics Oncology Market
    255. SIZE ESTIMATES & FORECAST, BY TECHNOLOGY, 2019-2035 (USD Billions)
    256. GCC
    257. Companion Diagnostics Oncology Market SIZE ESTIMATES & FORECAST, BY APPLICATIONS,
    258. 2035 (USD Billions)
    259. GCC Companion Diagnostics Oncology
    260. Market SIZE ESTIMATES & FORECAST, BY END USER, 2019-2035 (USD Billions)
    261. GCC
    262. Companion Diagnostics Oncology Market SIZE ESTIMATES & FORECAST, BY TEST TYPE,
    263. 2035 (USD Billions)
    264. PRODUCT LAUNCH/PRODUCT DEVELOPMENT/APPROVAL
    265. ACQUISITION/PARTNERSHIP
    266. LIST
    267. Of figures
    268. MARKET SYNOPSIS
    269. GCC
    270. COMPANION DIAGNOSTICS ONCOLOGY MARKET ANALYSIS BY TECHNOLOGY
    271. GCC
    272. COMPANION DIAGNOSTICS ONCOLOGY MARKET ANALYSIS BY APPLICATIONS
    273. GCC
    274. COMPANION DIAGNOSTICS ONCOLOGY MARKET ANALYSIS BY END USER
    275. GCC
    276. COMPANION DIAGNOSTICS ONCOLOGY MARKET ANALYSIS BY TEST TYPE
    277. KEY
    278. BUYING CRITERIA OF COMPANION DIAGNOSTICS ONCOLOGY MARKET
    279. RESEARCH
    280. PROCESS OF MRFR
    281. DRO ANALYSIS OF COMPANION DIAGNOSTICS
    282. ONCOLOGY MARKET
    283. DRIVERS IMPACT ANALYSIS: COMPANION DIAGNOSTICS
    284. ONCOLOGY MARKET
    285. RESTRAINTS IMPACT ANALYSIS: COMPANION
    286. DIAGNOSTICS ONCOLOGY MARKET
    287. SUPPLY / VALUE CHAIN: COMPANION
    288. DIAGNOSTICS ONCOLOGY MARKET
    289. COMPANION DIAGNOSTICS ONCOLOGY
    290. MARKET, BY TECHNOLOGY, 2025 (% SHARE)
    291. COMPANION DIAGNOSTICS
    292. ONCOLOGY MARKET, BY TECHNOLOGY, 2019 TO 2035 (USD Billions)
    293. COMPANION
    294. DIAGNOSTICS ONCOLOGY MARKET, BY APPLICATIONS, 2025 (% SHARE)
    295. COMPANION
    296. DIAGNOSTICS ONCOLOGY MARKET, BY APPLICATIONS, 2019 TO 2035 (USD Billions)
    297. COMPANION
    298. DIAGNOSTICS ONCOLOGY MARKET, BY END USER, 2025 (% SHARE)
    299. COMPANION
    300. DIAGNOSTICS ONCOLOGY MARKET, BY END USER, 2019 TO 2035 (USD Billions)
    301. COMPANION
    302. DIAGNOSTICS ONCOLOGY MARKET, BY TEST TYPE, 2025 (% SHARE)
    303. COMPANION
    304. DIAGNOSTICS ONCOLOGY MARKET, BY TEST TYPE, 2019 TO 2035 (USD Billions)
    305. BENCHMARKING
    306. OF MAJOR COMPETITORS

    GCC Companion Diagnostics Oncology Market Segmentation

     

     

     

    • Companion Diagnostics Oncology Market By Technology (USD Million, 2019-2035)

      • Next Generation Sequencing
      • Polymerase Chain Reaction
      • In Situ Hybridization
      • Immunohistochemistry

     

    • Companion Diagnostics Oncology Market By Applications (USD Million, 2019-2035)

      • Therapeutic Monitoring
      • Patient Stratification
      • Predictive Testing
      • Disease Diagnosis

     

    • Companion Diagnostics Oncology Market By End User (USD Million, 2019-2035)

      • Hospitals
      • Diagnostic Laboratories
      • Research Institutions
      • Pharmaceutical Companies

     

    • Companion Diagnostics Oncology Market By Test Type (USD Million, 2019-2035)

      • Genetic Tests
      • Protein Biomarker Tests
      • MicroRNA Tests
      • Pathological Analysis

     

     

     

     

     

     

    Report Infographic
    Free Sample Request

    Kindly complete the form below to receive a free sample of this Report

    Related Reports

    No regional reports available for this market.

    No country-specific reports available for this market.

    Customer Strories

    “I am very pleased with how market segments have been defined in a relevant way for my purposes (such as "Portable Freezers & refrigerators" and "last-mile"). In general the report is well structured. Thanks very much for your efforts.”

    Victoria Milne Founder
    Case Study

    Chemicals and Materials

    Global Magnesium Sulfate Market – Forecast till 2027